Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface

Abstract excerpt

breast cancer, acquired resistance remains a clinical challenge. The pseudokinase HER3, heterodimerisation partner of HER2, is widely implicated in the resistance to HER2-mediated therapy. Here, we show that lapatinib, an ATP-competitive inhibitor of HER2, is able to induce proliferation cooperatively with the HER3 ligand neuregulin. This counterintuitive synergy between inhibitor and growth factor depends on...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Glycosylation and Glycoproteins Research
• Share to HER2/EGFR in Cancer Research
• Share to Monoclonal and Polyclonal Antibodies Research